<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4140">
  <stage>Registered</stage>
  <submitdate>17/09/2013</submitdate>
  <approvaldate>17/09/2013</approvaldate>
  <nctid>NCT01973192</nctid>
  <trial_identification>
    <studytitle>Viral Pathogenesis of Early Cystic Fibrosis Lung Disease</studytitle>
    <scientifictitle>Viral Pathogenesis of Early Cystic Fibrosis Lung Disease</scientifictitle>
    <utrn />
    <trialacronym>Early CF</trialacronym>
    <secondaryid>1R01HL116211-01</secondaryid>
    <secondaryid>1R01HL116211-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Viral infection - To determine the effect(s) of viral infections on the evolution of endobronchial bacterial infection and inflammation in CF infants.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary exacerbation rate - To identify the impact of respiratory viruses on the onset, frequency, and duration of respiratory symptoms in CF infants diagnosed through newborn screening.</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Forced Expiratory Volume - To assess development of early lung disease as defined through physiological measures of forced expiratory flows, lung volumes, and ventilation inhomogeneity in CF infants.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Diagnosis of CF by newborn screening, at least one clinical feature of CF, and
             documented sweat chloride greater than 60 mEq/L by quantitative pilocarpine
             iontophoresis or compatible genotype with two identifiable mutant CFTR alleles.

          2. Less than 4 months of age at Screening Visit

          3. Ability to comply with study visits and study procedures as judged by site
             investigator.</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>4</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Intercurrent respiratory illness, defined as increase in cough, wheezing, or
             respiratory rate with onset 14 days before iPFT-bronchoscopy visit.

          2. Measured hemoglobin oxygen saturation less than 95% during the iPFT-bronchoscopy
             visit.

          3. History of adverse reaction to sedation.

          4. Clinically significant upper airway obstruction as determined by the site
             investigator.

          5. Severe gastroesophageal reflux, defined as persistent frequent emesis despite therapy.

          6. Major organ dysfunction, not including pancreatic dysfunction.

          7. Physical findings that would compromise the safety of the subject or the quality of
             the study data as determined by site investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>65</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Royal Children's Hospital - Melbourne</hospital>
    <hospital>Telethon Kids Institute - West Perth</hospital>
    <postcode> - Melbourne</postcode>
    <postcode>6872 - West Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Indiana University School of Medicine</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institutes of Health (NIH)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Heart, Lung, and Blood Institute (NHLBI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to test the hypothesis that early viral infections alter the
      bacterial flora and inflammatory profile in the airway and accelerate progression of
      pulmonary disease in infants with cystic fibrosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01973192</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephanie D. Davis, MD</name>
      <address>Indiana University School of Medicine</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>